Antibodies for use in agrin-deficient disorders
An anti-MuSK antibody targeting the MuSK Frizzled-like domain addresses the inadequacies of current agrin deficiency treatments by enhancing MuSK phosphorylation, improving neuromuscular transmission and muscle strength, providing a promising therapeutic approach for agrin deficiency-related disorders.
Patent Information
- Application Number
- PCT/EP2024/062981
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-28
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Current treatments for agrin deficiency-related disorders, such as congenital myasthenic syndromes, are inadequate, with existing medications like acetylcholinesterase inhibitors and 3,4-diaminopyridine being ineffective for specific subtypes and lacking standardized guidelines, leading to unsatisfactory symptom management and limited therapeutic options.
Development of an anti-MuSK antibody-based molecule that binds to the MuSK Frizzled-like domain, capable of activating MuSK phosphorylation, which is essential for neuromuscular junction development and maintenance, to treat agrin deficiency-related disorders by mimicking or enhancing the natural agrin-LRP4 interaction.
The anti-MuSK antibody improves neuromuscular transmission, increases muscle strength, and stabilizes neuromuscular junctions, offering a potential therapeutic solution for agrin deficiency-related disorders by enhancing MuSK signaling and phosphorylation, thereby addressing the limitations of existing treatments.
Smart Images

Figure 000156 
Figure 000157 
Figure 000158
Abstract
Citation Information
Patent Citations
Recombinant altered antibodies and methods of making altered antibodies
US5225539A
Humanized immunoglobulins
US5530101A
Humanized immunoglobulins
US5585089A
Antibodies with altered effector functions
US5624821A
DNA encoding antibodies with altered effector functions
US5648260A
